Viral hepatitis after liver transplantation: A brief overview

Table 2 Efficacy of directly acting antiviral based therapy in patients with hepatitis c virus related decompensated cirrhosis

Ref.	Patient population	SVR rates	Additional comments
Premkumar et al[44], 2024	1152 patients with DC (87% GT-3)	82%-90% with sofosbuvir + velpatasvir + ribavirin or sofosbuvir + daclatasvir + ribavirin	Probably the largest study showing effect of directly acting antivirals in DC and GT-3
Belperio et al[45], 2019	243 patients with GT-3 related DC	87.5%-100% in various arms with sofosbuvir + daclatasvir/velpatasvir with or without ribavirin	Higher SVR (up to 92%) in patients with compensated cirrhosis
Lim et al[46], 2018	667 patients with GT-1, 231 non-transplanted GT	87.5%-100% with ledipasvir + sofosbuvir with or without ribavirin	Higher SVR with compensated cirrhosis and in patients having normal bilirubin with high albumin
Manns et al[47], 2016	333 patients with DC, with GT-1 and 4	CTP-B: 87%-96%, CTP-C: 78%-85%	17 patients died during the study period
Poordad et al[48], 2016	60 patients with advanced cirrhosis	CTP-A: 93%, CTP-B: 93%, CTP-C: 56%, regimen used-sofosbuvir + daclatasvir + ribavirin	Presence of DC was a negative predictor of SVR
Reddy et al[49], 2017	240 patients with model for end stage liver disease score more than 10	35%-84% with sofosbuvir + simeprevir + ribavirin or sosfosbuvir + ribavirin	Low SVR rates with GT-1a; SVR only 35% with GT-3
Curry et al[50], 2015	267 patients with DC, GT-3: 13%, GT-1: 75%	Sofosbuvir + velpatasvir-24 weeks (86%), sofosbuvir + velpatasvir-12 weeks (83%), sofosbuvir + velpatasvir + ribavirin (94%)	Serious adverse events in 16%-19%
Charlton et al[51], 2015	337 DC patients with GT-1	86%-89% with sofosbuvir + ledipasvir + ribavirin for 12-24 weeks	All but 1 patient with GT-1

CTP: Child-Turcotte-Pugh; DC: Decompensated cirrhosis; GT: Genotype; SVR: Sustained viral response.